Lightnews — Scholar-powered news

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 2h

📊 Phase III C-POST trial showed Libtayo reduced the risk of recurrence or death by 68% vs. placebo, marking a potential shift in the CSCC treatment paradigm.

🔗 Read more: bit.ly/ONCOnews09O-1

#ONCOnews #OncoAlert #OncEd #FDAApproval #Immunotherapy #Oncology #CancerTreatment

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 2h

🚨 FDA Approval Alert!

✅ Libtayo® (cemiplimab-rwlc) is now the first and only immunotherapy approved in the U.S. for adjuvant treatment of high-risk cutaneous squamous cell carcinoma (CSCC) after surgery and radiation.

1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 23h

⬇️ If you’re an HCP, download our app now : bit.ly/download_ONC...

#ONCOassist #OncoAlert #Oncology #DigitalHealth #HealthTech #ClinicalTools #OncologyApp #CancerCare #Oncologist #MedicalApps #OncologyCommunity #HealthCareProfessionals #OncTwitter

ONCOassist

bit.ly

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 23h

🌐 AI platforms like ChatGPT & Gemini spotlight ONCOassist as the go- to oncology app worldwide.

✅ Trusted by 100,000+ Oncology HCPs across the globe
✅ Powered by evidence-based tools
✅ Designed to make daily practice simpler

📲 Your all-in-one oncology app, crafted for oncology professionals.

1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 2d

Download the ONCOassist app:
📥 iOS: apple.co/4iuMxfS
📥 Android: bit.ly/oncoassiston...
📥Webapp: bit.ly/ONCOassistOn...

‎ONCOassist

‎Please note: This application, as a decision-support aid, is to be used by a practicing healthcare professional(“HCP”) and does not replace clinical judgement. It is not designed for use by…

apple.co

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 2d

Access the published research: 👇🏻
academic.oup.com/oncolo/artic...

Global variations in oncology professionals’ confidence levels for managing antibody–drug conjugate toxicities: a cross-continental survey

AbstractBackground. Antibody–drug conjugates (ADCs) represent a promising therapeutic approach in oncology, but managing their toxicities remains challengi

academic.oup.com

1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 2d

Are oncologists ready to manage ADC toxicities?
Dr. Michele Maffezzoli shares results from a global ONCOassist survey revealing confidence gaps between continents, roles & subspecialties.

📺 Watch: youtu.be/t8mHHX2--yE

🌐 Learn more at: oncoassist.com

#Oncology #ADC #ToxicityManagement #ONCOassist

1 1 1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 2d

📈 The treatment also showed a highly significant improvement in progression-free survival in the TROPION-Breast02 trial.

🔗 Read more: bit.ly/ONCOnews07O-1

#ONCOnews #OncoAlert #OncEd #BreastCancer #CancerResearch #ClinicalTrials #Oncology

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 2d

🎗️BREAKING: Phase III Results!

💊 AstraZeneca & Daiichi Sankyo’s Datroway (datopotamab deruxtecan) becomes the first and only therapy to show a significant overall survival benefit vs. chemotherapy in patients with metastatic triple-negative breast cancer ineligible for immunotherapy.

1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 3d

✨ Key features:

✅ Side-by-side comparison of novel mCRPC therapies
📊 Data from the latest clinical trials
🕒 Quick access to PFS & OS outcomes
🎯 Supports treatment planning across therapy lines
💡 Streamline your workflow & enhance decision-making in mCRPC care.
#ProstateCancer #CancerCare

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 3d

🧰 Discover Metastatic Castrate Resistant Prostate Cancer Tool in ONCOassist!

Have you tried the mCRPC Tool yet? Designed to support oncology professionals treating metastatic castration-resistant prostate cancer.

🔗 Click here to access the tool now 👉 bit.ly/ONCOassist_mCRPC_Tool

#Oncology #mCRPC

1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 6d

#ONCOnews #OncoAlert #OncEd #LungCancer #SCLC #FDAApproval #CancerTreatment

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 6d

🚨 FDA Approval Alert !

✅ Roche’s Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) in combination with Zepzelca® (lurbinectedin) approved as the first-line maintenance therapy for ES-SCLC.

🔗 Read more: bit.ly/ONCOnews3O-1

1 1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 6d

🎧 LISTEN ON OTHER PLATFORMS:
🔹 Spotify: bit.ly/KatyWinckwor...
🔹 Apple Podcasts: apple.co/42Qclgj

Oncology Spotlight: Katy Winckworth on breaking barriers in Cancer Care with NCCN’s Global Program

👉 Visit https://oncoassist.com/ to streamline patient care with cutting-edge tools, guidelines, and calculators! 🔬In this episode of Oncology Spotlight, we sit down with Katy Winckworth-Prejsnar,…

youtu.be

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 6d

🔁 ICYMI:
Katy Winckworth-Prejsnar of @NCCN joined #OncologySpotlight to share how they’re adapting guidelines to fight cancer globally 🌍

🎧 Catch up now: youtu.be/sP4biZu-dHs

#GlobalOncology #CancerEquity #NCCN #ONCOassist #OncoAlert #GlobalCancerCare

1 1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 8d

Download the ONCOassist app:
📥 iOS: apple.co/4iuMxfS
📥 Android: bit.ly/oncoassiston...
📥Webapp: bit.ly/ONCOassistOn...

‎ONCOassist

‎Please note: This application, as a decision-support aid, is to be used by a practicing healthcare professional(“HCP”) and does not replace clinical judgement. It is not designed for use by…

apple.co

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 8d

🧮Calculate Carboplatin Dose using Wright Equation in 20 seconds with
@ONCOassist

#ONCOassist #WrightEquation #Carboplatin #GFR #OncologyTools #DigitalHealth #ClinicalCalculator #OncologyApp #ChemotherapyDosing #RenalFunction

1 1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 8d

🔗 Read more: bit.ly/ONCOnews30S-3

#ONCOnews #OncoAlert #OncEd #PrecisionMedicine #ClinicalUpdate #CancerResearch

Test Banner

bit.ly

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 8d

🚨Clinical Update – Uterine Cancer!

🧬 Signatera™ is a personalized ctDNA test that detects MRD by identifying tiny traces of tumor DNA in the blood. It’s custom-designed for each patient to monitor for recurrence.

🔬 In a recent study, Signatera™ identified 100% of uterine cancer recurrences.

1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 8d

🚨 New Episode: How is @NCCN bringing cancer care equity to the world?

🎙️ On #OncologySpotlight, Katy Winckworth-Prejsnar shares how NCCN’s Global Program is adapting guidelines for real-world impact 🌍

Watch now 🎧: youtu.be/sP4biZu-dHs

#GlobalOncology #CancerEquity #NCCN #ONCOassist #GlobalCancer

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 9d

#ONCOnews #OncoAlert #OncEd #BreastCancer #FDAApproval #Oncology

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 9d

🚨 FDA Approval Alert !

🧬 Guardant360® CDx approved as a companion diagnostic for Eli Lilly’s Inluriyo™ (imlunestrant) in ESR1-mutated advanced breast cancer

✅ Marks the second FDA-approved indication for Guardant360 CDx in breast cancer

🔗 Read more: bit.ly/ONCOnews30S-2

1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 9d

#ONCOnews #OncoAlert #OncEd #Phase3 #CancerResearch #Oncology

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 9d

🚨BREAKING:

Phase III Clinical Trial Update!

✨ Enhertu (fam-trastuzumab deruxtecan-nxki) shows superior iDFS vs.T-DM1 in DESTINY-Breast05

🧬 Benefit seen in high-risk early breast cancer following neoadjuvant therapy

🔗 Read more: bit.ly/ONCOnews30S-1

1

ONCOassist® | The go-to oncology app @oncoassist.bsky.social · 13d

#ONCOnews #OncoAlert #OncEd #FDAApproval #BreastCancer #CancerResearch